Keiichi Himuro
Matsudo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Quantitative Assessment of Dysphagia in Myasthenia Gravis.
Journal: Internal medicine (Tokyo, Japan)
Published: October 20, 2024
Serum pentraxin 3 concentration correlates with disease severity in patients with myasthenia gravis.
Serum pentraxin 3 concentration correlates with disease severity in patients with myasthenia gravis.
Journal: Clinical neurology and neurosurgery
Published: April 04, 2022
Long-term outcomes and prognostic factors in generalized myasthenia gravis.
Journal: Journal of neurology
Published: December 08, 2020
Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: October 30, 2020
Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.
Journal: Clinical and experimental immunology
Published: June 19, 2020
Changes in serum complements and their regulators in generalized myasthenia gravis.
Journal: European journal of neurology
Published: June 03, 2020
Increased serum acetylcholine receptor α1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis.
Journal: Journal of neuroimmunology
Published: November 20, 2019
Frequency and features of myasthenia gravis developing after thymectomy.
Journal: European journal of neurology
Published: March 29, 2019
Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis.
Journal: Journal of the neurological sciences
Published: March 10, 2019
Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis.
Journal: Journal of the neurological sciences
Published: March 10, 2018
A clinical predictive score for postoperative myasthenic crisis.
Journal: Annals of neurology
Published: March 17, 2017
A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: September 29, 2016
Last Updated: 09/26/2026